Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

Controlling respiratory syncytial virus: Real-life data from Luxembourg Jan 29, 2024 RSV vaccine program for older people in Scotland shows 62% drop in hospitalizations ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...